BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 18.10.2019 | 07:00

BB Biotech AG publishes its interim report

BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

18-Oct-2019 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media release of October 18, 2019

Interim report of BB Biotech AG as at September 30, 2019

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2019, which covers the results of its business activities for the first nine months of 2019.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2019 amounted to CHF 172 mn (profit of CHF 172 mn in the same period 2018). In the third quarter a loss of CHF 382 mn (profit of CHF 242 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported result reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at September 30, 2019 can be downloaded at www.bbbiotech.com.

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, Tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch

www.bbbiotech.com

Company profile
BB Biotech AG invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector.
BB Biotech AG is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech AG's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.


18-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
<

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Wirecard AG: Vorläufiges Ergebnis 2019

14. Februar 2020, 07:30

Aktueller Webcast

home24 SE

Trading Update FY 2019

11. Februar 2020

Aktuelle Research-Studie

All for One Group AG

Original-Research: All for One Group AG (von BankM AG): Kaufen

13. Februar 2020